GWAS+ health science service platform, KEYIN Health Science, began operation.

The first instance project of whole process gene testing application productization solution, neuroblastoma progress monitoring, has more than 5000 cases in total.

The second Gene Health Industry Conference was held in Taizhou Pharmaceutical City successfully.

Awarded Zhongguancun High-Tech Enterprise Certificate.

Demonstrative platform of decentralized data value sharing community ecological solution based on blockchain and smart contract technology launched online.

Awarded National High-Tech Enterprise Certificate.

Beijing Keyin Evergreen Institutes for Medical Research Company Limited set up. A great number of experts in the field of medicine and life science have been recruited or contracted for long term research cooperation.

The first batch of independently developed intelligent medical service platform software was awarded the copyright registration certificate of computer software by the National Copyright Administration.

The project of KTB tumor burden quantification monitoring officially launched and carried out multiple collaborative projects with hospitals for tumor treatment response evaluation, personalized clinical scheme research and patient consulting services.

Multi-centered doctor-patient collaborative rare diseases research platform launched. It could provide online intelligent assisted primary diagnosis covering more than 4000 rare genetic diseases, fully structured data sharing management, remote collaborative diagnosis and multi-centered parties online collaborative research service.

Chunxiang Wang, Co-founder of KEYINTT, participated in promoting establishment of Biological Industry Promotion Committee of China Genetic Society and was entitled as director of Expert Committee. The startup of Expert Committee i.e. the first Gene Health Industry Conference was held in Taizhou Pharmaceutical City successfully. This highly praised meeting had more than thousand industry insiders attending.

20 entrepreneurs and genetic biologists jointly invested 30 million RMB to set up Beijing KEYIN Technology Company Limited, aiming for promoting the inclusive application of international advanced intelligent medical technology in China.